Prevalence and Risk Factors for Anemia in a Population With Hidradenitis Suppurativa.
anemia
hidradenitis suppurativa
prevalence
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
10 Dec 2020
10 Dec 2020
Historique:
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS) is an inflammatory disease presenting as nodules evolving into scarred plaques. HS is associated with many co-morbidities, including anemia of chronic disease, though few studies report on this association. This study evaluated the prevalence of anemia among the HS patient population and potential associations between risk factors for HS and anemia development. Records diagnosed HS patients in one private practice (BR) were reviewed by investigators. The 92-patient cohort was evaluated for multiple data-points and responses grouped based on age, gender, ethnicity, body mass index (BMI), smoking status, and comorbidities. Data were analyzed using STATA to perform descriptive analysis and bivariate analysis. The prevalence of anemia in this cohort was 41.3%. Of anemic patients, the majority were men (65.2%), African American (60.6%), and never/former smokers (48.6%). There was a significant increase in the odds of developing anemia in HS patients that are men (odds ratio (OR) 3.8) and African American (OR 3.5). We show that the prevalence of anemia in an HS patient population greatly surpasses that of the U.S. population (~5%). It is clear that anemia is a significant complication for HS patients. We hope that physicians can recognize the importance of screening patients with HS for anemia to medically optimize treatment for their patients.
Sections du résumé
BACKGROUND
BACKGROUND
Hidradenitis suppurativa (HS) is an inflammatory disease presenting as nodules evolving into scarred plaques. HS is associated with many co-morbidities, including anemia of chronic disease, though few studies report on this association.
OBJECTIVES
OBJECTIVE
This study evaluated the prevalence of anemia among the HS patient population and potential associations between risk factors for HS and anemia development.
METHODS
METHODS
Records diagnosed HS patients in one private practice (BR) were reviewed by investigators. The 92-patient cohort was evaluated for multiple data-points and responses grouped based on age, gender, ethnicity, body mass index (BMI), smoking status, and comorbidities. Data were analyzed using STATA to perform descriptive analysis and bivariate analysis.
RESULTS
RESULTS
The prevalence of anemia in this cohort was 41.3%. Of anemic patients, the majority were men (65.2%), African American (60.6%), and never/former smokers (48.6%). There was a significant increase in the odds of developing anemia in HS patients that are men (odds ratio (OR) 3.8) and African American (OR 3.5).
CONCLUSIONS
CONCLUSIONS
We show that the prevalence of anemia in an HS patient population greatly surpasses that of the U.S. population (~5%). It is clear that anemia is a significant complication for HS patients. We hope that physicians can recognize the importance of screening patients with HS for anemia to medically optimize treatment for their patients.
Identifiants
pubmed: 33457122
doi: 10.7759/cureus.12015
pmc: PMC7797412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12015Informations de copyright
Copyright © 2020, Resnik et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2016 Nov 15;11(11):e0166635
pubmed: 27846276
Arch Dermatol. 1968 Aug;98(2):138-40
pubmed: 5667225
N Engl J Med. 2005 Mar 10;352(10):1011-23
pubmed: 15758012
J Eur Acad Dermatol Venereol. 2016 Jan;30(1):174-5
pubmed: 25185839
J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3
pubmed: 19293006
Dermatol Online J. 2013 Jun 15;19(6):18558
pubmed: 24011308
Dermatoendocrinol. 2010 Jan;2(1):9-16
pubmed: 21547142
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1366-72
pubmed: 26446344